STOCK TITAN
  1. Home
  2. News
  3. INCY

Incyte Corp. - INCY STOCK NEWS

Welcome to our dedicated news page for Incyte (Ticker: INCY), a resource for investors and traders seeking the latest updates and insights on Incyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incyte's position in the market.

News
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
Rhea-AI Summary
Incyte (INCY) reports strong FY'23 with total net product and royalty revenues of $3.7 billion, a 14% increase YoY. Key highlights include Jakafi net revenues of $2.6 billion (+8%) and Opzelura cream net revenues of $109 million in Q4'23. The company aims for over 10 new launches by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
earnings
-
News
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
Rhea-AI Summary
Incyte has entered into an asset purchase agreement with MorphoSys AG, gaining exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® and outside of the U.S. as Minjuvi®. The new agreement allows Incyte to realize significant operating efficiencies and cost synergies. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development, and MorphoSys will no longer be eligible to receive future milestone, profit split, and royalty payments. Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is currently in Phase 3 trials for multiple indications, including first-line DLBCL, relapsed or refractory follicular lymphoma (FL), and relapsed or refractory marginal zone lymphoma (MZL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
none
-
News
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
Rhea-AI Summary
Incyte (Nasdaq:INCY) has scheduled its Q4 & YE 2023 financial results conference call and webcast for February 13, 2024. The press release will be at 7:00 a.m. ET, followed by the conference call at 8:00 a.m. ET. The company will provide a domestic and international dial-in number, along with a conference ID number for participation. A replay of the conference call will be available for thirty days, and the webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences earnings
News
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Incyte (INCY) highlights growth opportunities and provides key updates across its investigational pipeline and commercial portfolio at the 42nd Annual J.P. Morgan Healthcare Conference. The company announces new positive topline results from Phase 2 trial evaluating ruxolitinib cream (Opzelura®) in adults with hidradenitis suppurativa (HS) and preliminary results from Phase 1 study of INCB123667 (CDK2i). The presentation underscores potential high-impact launches across Oncology and Inflammation & Autoimmunity to drive sustainable long-term growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
News
Incyte to Present at Upcoming Investor Conferences
Rhea-AI Summary
Incyte (Nasdaq:INCY) will present at the Goldman Sachs Annual Healthcare CEOs Unscripted Conference on January 4, 2024, and at the 42nd Annual J. P. Morgan Healthcare Conference on January 8, 2024. The presentations will be webcast live and can be accessed at Investor.Incyte.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
conferences
-
News
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
Rhea-AI Summary
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) announced the successful results from the Phase 2 AGAVE-201 trial of axatilimab for chronic GVHD. The trial met its primary endpoint, with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment. The data were featured in the Plenary Scientific Session at the 65th American Society of Hematology Annual Meeting 2023. Incyte and Syndax expect to file a Biologics License Application (BLA) for axatilimab by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
News
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Rhea-AI Summary
Incyte (Nasdaq:INCY) will present more than 40 abstracts at the ASH 2023 conference, featuring data from its hematology and oncology products. The Plenary Scientific Session will showcase the results of the AGAVE-201 trial evaluating axatilimab in patients with chronic GVHD. Incyte will also host an analyst and investor event to discuss the key data presentations at ASH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
News
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Rhea-AI Summary
Incyte reports Q3 2023 financial results with total revenues of $919 million, a 12% YoY increase. Jakafi net product revenues were $636 million, up 3% YoY. Opzelura cream net product revenues were $92 million, up 141% YoY. The company achieved positive results in a Phase 2 study of povorcitinib in prurigo nodularis and plans to initiate a Phase 3 study in 2024. Incyte also provided updates on its clinical development portfolio and highlighted progress in myeloproliferative neoplasms (MPNs).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
earnings
-
News
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
Rhea-AI Summary
Incyte recognized as a top employer for the sixth consecutive year by Science magazine, ranking second on the list and praised for loyal employees and social responsibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
none
News
Incyte to Present at Upcoming Investor Conferences
Rhea-AI Summary
Incyte to present at investor conferences in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
Stock INCY logo
Incyte Corp.

Nasdaq:INCY

INCY Rankings

#736 Ranked by Market Cap
#3820 Ranked by Stock Gains
N/A Ranked by Dividends

INCY Stock Data

12.09B
186.98M
1.58%
100.2%
3.59%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
US
Wilmington

About INCY

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.